Fabrication of carboxymethylcellulose hydrogel containing β-cyclodextrin–eugenol inclusion complexes for promoting diabetic wound healing. (January 2020)

• Record Type: Journal Article
• Authors: Li, Mengdie; Li, Fang; Wang, Tao; Zhao, Liang; Shi, Yijie
• Is Part Of: Journal of biomaterials applications. Volume 34:Number 6(2020)
• Page Start: 851
• Page End: 863
• Publication Date: 2020-01
• Subjects: Inflammation -- angiogenesis -- nuclear factor kappa-B -- eugenol -- hydrogel; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1177/0885328219873254
• Languages: English
• ISSNs: 0885-3282

Abstract

The difficult healing of wounds caused by diabetes remains a challenging clinical problem. The activation of nuclear factor kappa-B as a key factor contributes to prolonged inflammation and inhibition of angiogenesis. As a natural antioxidant, eugenol may downregulate the lectin-like oxidized low-density lipoprotein receptor-1 and inhibit the activation of nuclear factor kappa-B in endothelial cells. However, eugenol shows poor solubility, pungent odor, and volatility, thus impeding its clinical application as a potential therapeutic agent. This study developed a novel bioactive carboxymethylcellulose hydrogel loaded with inclusion complexes of eugenol with β-cyclodextrin (eugenol–β-cyclodextrin/carboxymethylcellulose hydrogel) to regulate lectin-like oxidized low-density lipoprotein receptor-1-induced activation of nuclear factor kappa-B to enhance angiogenesis and inhibit inflammation for accelerating diabetic wound healing in vivo. It was found that eugenol–β-cyclodextrin/carboxymethylcellulose hydrogel exhibited remarkable antibacterial activity in vivo and in vitro. Furthermore, it accelerated diabetic wound healing by reducing the lectin-like oxidized low-density lipoprotein receptor-1/nuclear factor kappa-B-induced dysfunction in endothelial cells and promoting angiogenesis.